After long road, Lilly amyloid detection agent crosses US finish line
This article was originally published in Scrip
Executive Summary
After initially being rejected last year by the US FDA, Lilly's non-therapeutic radiopharmaceutical Amyvid (florbetapir F 18 injection) gained regulators blessing to enter the US market as a brain imaging agent of beta-amyloid plaques in patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive decline.
You may also be interested in...
ADDF’s Fillit On FDA’s Tough Aducanumab Decision, Advances In Alzheimer’s
The pending US FDA decision on Biogen’s drug overshadows progress in Alzheimer’s diagnosis, symptomatic treatments and the need to keep studying anti-tau therapies after Roche’s setback.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.